medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2006, Number 1

<< Back Next >>

Rev Mex Urol 2006; 66 (1)

Síndrome de deficiencia parcial de andrógenos

Cruz TJ, Viveros CC, Skrom-K G, Lugo GJA, Moreno RR

Language: Spanish
References: 23
Page: 3-11
PDF size: 357.77 Kb.


ABSTRACT

The improvement in health and sanitation services, advances in medical and World technology have progressively expanded life expectancy, reason why it is said “the World is getting old.” For this reason is imperative to have knowledge of the pathologies that affect the adult age, andropause or partial androgen deficiency in the ageing man being one of them. This pathology has taken major importance in modern urology.
Objectives. To determine the prevalence of Partial Androgen Deficiency Syndrome in a group of Mexican population at Hospital Juarez of Mexico, and determine the age groups most affected by it.
Material and Methods. An observational, prospective, clinical study was done taking as a sample 100 patients between the ages 40 and 70 years old from the outpatient consult service in our hospital. They were divided into three groups, 40 to 50, 51 to 60 and 61 to 70 years old. All groups were given the ADAM (Androgen Decline of Aging Male) test and the AMS (Androgen Male Survey) Questionnaire, also blood samples were taken to determine their levels of testosterone. Prevalence percentages for androgen partial deficiency were utilized in each age group and on the total number of patients. The prevalence was 8.8%, 41.67% and 52.5% for the first, second and third groups, respectively, with a 34% prevalence in the group as a whole.
Conclusions. The prevalence of the androgen partial deficiency syndrome at our hospital was 34%, and show an important rise in patients over 50 years old.


REFERENCES

  1. Morales A, Heaton JPW, Carson CC. Andropause: a misnomer for a true clinical entity. J Urol. 2000;163: 705-12.

  2. Morales A, Heaton J. Hormonal erectile dysfunction-evaluation and management. Urol Clin North Am. 2001;28:279-88.

  3. Morley JE, Chariton E, Patrick, et al. Validation of screening questionnaire for androgen deficiency in aging men. Metabolism. 2000;49:1239-42.

  4. Gooren LJG. The age-related decline of androgen levels in men: clinically significant? Br J Urol. 1996; 78:763-6.

  5. Morales A, Tenover JL. El anciano con déficit de andrógenos. Clin Urol North. 2002;(4):985-992.

  6. Perry HM, Miller DK, Patrick P, Morley JE. Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism. 2000;49:1085-91.

  7. Matsumoto AM. Andropause: clinical implications of the decline in serum testosterona leves with aging in men. J Gerontol Biol SCI Med. 2002;57.

  8. Morales A, Morley J, Heaton J. The aging male; the practical approach to andropause and androgen therapy. AUA Meeting 2000, 2001, 2002, 2003.

  9. United Nations Department for economical and Social Information and Policy Analisis. Population division: world population prospects. The 1994 revision, document 145. New York: United Nations, 1995.

  10. Wick G, Jansen-Dürr P, Berger P, et al. Diseases of aging. Vaccine. 2000;18:1567-83.

  11. Guyton A.C., Tratado de Fisiología Médica., 8a Ed. McGraw Hill Interamericana; 1992. p.979.

  12. Tenover JS. Effects of testosterona supplementation in the aging male. J Clin Endocrinol Metab. 1992;75: 1092-8.

  13. Boonen S, Vanderschueren D, Geusens P, Bouillon R. Age-associated endocrine deficiencies as potential determinants of femoral neck (type II) osteoporotic fracture ocurrence in elderly men. Mt J Androl. 1997;20:134-43.

  14. Goldray D, Weisan Y, Jaccard N, et al. Decreased bone density in elderly men treated with the gonadotropin- releasing hormone agonist decapeptyl. J Clin Endocrinol Metab. 1993;76:288-90.

  15. Shahidi NT. Androgens and erythropoiesis. N Engl J Med. 1973;289:72-80.

  16. Campbell, Urología. Sexta Edición, Editorial Panamericana, México. p. 2331-2340.

  17. Tenover JL. Male hormone replacement therapy including “andropause”. Endocrinol Metab Clin North Am. 1998;27:969-87.

  18. Joel MH Teichman. 20 problemas comunes en urología; 256-263.

  19. Morley JE, Chariton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry HM. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;85:3276-82.

  20. Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C, Hummel W. A new “aging males symptoms” rating scale. Aging Male. 1999;2:105-14.

  21. Heinemann LAJ, Saad F, Thiele K, Wood-Dauphinee S. The aging males symptoms rating scale: cultural and liguistic validation into English. Aging Male. 2001;4:14-22.

  22. Tremblay RR, Morales A. Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency. Aging Male. 1998;1:213-8.

  23. Jaspersen Gastelum J. Andropausia. Mitos y realidades. Boletín del Colegio Mexicano de Urología. 2004; XIX (1):36-40.




2020     |     www.medigraphic.com